<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02516241</url>
  </required_header>
  <id_info>
    <org_study_id>D419BC00001</org_study_id>
    <nct_id>NCT02516241</nct_id>
  </id_info>
  <brief_title>Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer</brief_title>
  <official_title>A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line&#xD;
      MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab&#xD;
      Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label, controlled, multi-center, global Phase III study to&#xD;
      determine the efficacy and safety of MEDI4736 (Durvalumab) monotherapy and MEDI4736&#xD;
      (Durvalumab) in combination with tremelimumab versus SoC (cisplatin + gemcitabine or&#xD;
      carboplatin + gemcitabine doublet) first-line chemotherapy in treatment-na√Øve patients with&#xD;
      histologically or cytologically documented, unresectable, Stage IV transitional cell&#xD;
      carcinoma (transitional cell and mixed transitional/non-transitional cell histologies) of the&#xD;
      urothelium (including renal pelvis, ureters, urinary bladder, and urethra) and to allow&#xD;
      sufficient flexibility for Investigators and patients to select the agents that reflect their&#xD;
      normal clinical practice and national guidelines. The patients enrolled in the study will be&#xD;
      randomized 1:1:1 to receive treatment with combination therapy, monotherapy, or SoC&#xD;
      (cisplatin + gemcitabine or carboplatin + gemcitabine, based on cisplatin eligibility).&#xD;
      Patients will be treated with MEDI4736 (Durvalumab) or MEDI4736 (Durvalumab) with&#xD;
      tremelimumab, or treated with SoC until progressive disease (PD) is confirmed, unacceptable&#xD;
      toxicity occurs, withdrawal of consent, or another discontinuation criterion is met. Patients&#xD;
      will be followed for up to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2, 2015</start_date>
  <completion_date type="Anticipated">March 29, 2024</completion_date>
  <primary_completion_date type="Actual">January 27, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis Set</measure>
    <time_frame>From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To Assess the Efficacy of Durvalumab Monotherapy Versus SoC in Terms of OS in PD-L1-High Analysis Set</measure>
    <time_frame>From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS, Full Analysis Set - Durvalumab Monotherapy vs SoC</measure>
    <time_frame>From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC</measure>
    <time_frame>From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy</measure>
    <time_frame>From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alive at 24 Months (OS24), Full Analysis Set</measure>
    <time_frame>From randomization date until death due to any cause, assessed up to 24 months or the data cut-off date (27JAN2020).</time_frame>
    <description>Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alive at 24 Months (OS24), PD-L1-High Analysis Set</measure>
    <time_frame>From randomization date until death due to any cause, assessed up to 24 months or the data cut-off date (27JAN2020).</time_frame>
    <description>Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alive at 24 Months (OS24), PD-L1-Low/Negative Analysis Set</measure>
    <time_frame>From randomization date until death due to any cause, assessed up to 24 months or the data cut-off date (27JAN2020).</time_frame>
    <description>Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>Progression free survival (PFS) (per RECIST 1.1, as assessed by investigator) was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to progression.&#xD;
Median PFS was calculated using the Kaplan-Meier technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>Progression free survival (PFS) (per RECIST 1.1, as assessed by investigator) was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to progression.&#xD;
Median PFS was calculated using the Kaplan-Meier technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>Progression free survival (PFS) (per RECIST 1.1, as assessed by investigator) was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to progression.&#xD;
Median PFS was calculated using the Kaplan-Meier technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alive and Progression-free at 12 Months (APF12), Full Analysis Set</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).</time_frame>
    <description>Alive and progression-free at 12 months (APF12) was defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by investigator) at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alive and Progression-free at 12 Months (APF12), PD-L1-High Analysis Set</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).</time_frame>
    <description>Alive and progression-free at 12 months (APF12) was defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by investigator) at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alive and Progression-free at 12 Months (APF12), PD-L1-Low/Negative Analysis Set</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).</time_frame>
    <description>Alive and progression-free at 12 months (APF12) was defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by investigator) at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS2, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until first confirmed disease progression, disease then assessed per local practice until 2nd progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>Time from randomization to second progression or death (PFS2) was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy or death (ie, date of PFS2 event or censoring - date of randomization +1).&#xD;
Median PFS2 was calculated using the Kaplan-Meier technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS2, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until first confirmed disease progression, disease then assessed per local practice until 2nd progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>Time from randomization to second progression or death (PFS2) was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy or death (ie, date of PFS2 event or censoring - date of randomization +1).&#xD;
Median PFS2 was calculated using the Kaplan-Meier technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS2, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until first confirmed disease progression, disease then assessed per local practice until 2nd progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>Time from randomization to second progression or death (PFS2) was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy or death (ie, date of PFS2 event or censoring - date of randomization +1).&#xD;
Median PFS2 was calculated using the Kaplan-Meier technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR), Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR), PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR), PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) Based on BICR Assessment According to RECIST 1.1 - Responses Are Confirmed - Durvalumab Cisplatin Ineligible Population</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (01NOV2017, a maximum of 3 years).</time_frame>
    <description>Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.&#xD;
unconfirmed responses are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) at 6 Months, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 6 months or the data cut-off date (27JAN2020).</time_frame>
    <description>Disease control rate (DCR) at 6 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 24 weeks (-7 days, i.e., 161 days), following the start of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) at 6 Months, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 6 months or the data cut-off date (27JAN2020).</time_frame>
    <description>Disease control rate (DCR) at 6 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 24 weeks (-7 days, i.e., 161 days), following the start of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) at 6 Months, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 6 months or the data cut-off date (27JAN2020).</time_frame>
    <description>Disease control rate (DCR) at 6 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 24 weeks (-7 days, i.e., 161 days), following the start of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) at 12 Months, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020)</time_frame>
    <description>Disease control rate (DCR) at 12 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 48 weeks (-7 days, i.e., 329 days), following the start of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) at 12 Months, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).</time_frame>
    <description>Disease control rate (DCR) at 12 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 48 weeks (-7 days, i.e., 329 days), following the start of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) at 12 Months, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).</time_frame>
    <description>Disease control rate (DCR) at 12 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 48 weeks (-7 days, i.e., 329 days), following the start of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR), Full Analysis Set</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR), PD-L1-High Analysis Set</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR), PD-L1-Low/Negative Analysis Set</measure>
    <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Durvalumab, Pharmacokinetic Analysis Set</measure>
    <time_frame>Pre-dose and within 1 hour after end of infusion at Week 0, 12 and 24, pre-dose at week 4, and at follow-up Month 3.</time_frame>
    <description>Blood samples were collected to determine the serum concentration of durvalumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Tremelimumab, Pharmacokinetic Analysis Set</measure>
    <time_frame>Pre-dose and within 1 hour after end of infusion at Week 0, 12 and 24, pre-dose at week 4, and at follow-up Month 3.</time_frame>
    <description>Blood samples were collected to determine the serum concentration of tremelimumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab, Safety Analysis Set - ADA Evaluable Patients</measure>
    <time_frame>At week 0, 4, 12 and 24, and at follow-up Month 3.</time_frame>
    <description>Serum Samples will be measured for the presence of ADAs and ADA-neutralizing antibodies for Durvalumab using validated assays. Tiered analysis will be performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-na√Øve validation samples will be used. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The category may include patients meeting these criteria who are ADA positive at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-Drug Antibody (ADA) Response to Tremelimumab, Safety Analysis Set - ADA Evaluable Patients</measure>
    <time_frame>At week 0, 4, 12 and at follow-up Month 3.</time_frame>
    <description>Serum Samples will be measured for the presence of ADAs and ADA-neutralizing antibodies for Tremelimumab using validated assays. Tiered analysis will be performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-na√Øve validation samples will be used. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The category may include patients meeting these criteria who are ADA positive at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</measure>
    <time_frame>At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>the change from baseline in the following total/index scores will be evaluated as secondary endpoints: FACT-BL TOI (refer to as TOI), FACT-BL Total score, and NFBlSI-18 score.&#xD;
All the 5 subscales (PWB (0-28), FWB (0-28), EWB (0-24), SWB (0-28), and BlCS(0-48)) are summed as the FACT-BL total score (range 0-156), while the sum of PWB, FWB and BICS constitutes the FACT-BL TOI (range 0-104).&#xD;
NFBlSI-18 (range 0-72) is based on the scores of 16 items (GP4, C2, BL1, GP3, GE6, GE1, C6, BL5, GF5, GP2, GP1, GP6, C3, GP5, GF3, GF7) and 2 extra items &quot;I feel weak all overall&quot; and &quot;I feel light-headed (dizzy)&quot;. The range of each item is 0-4.&#xD;
Higher score represent worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</measure>
    <time_frame>At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>the change from baseline in the following total/index scores will be evaluated as secondary endpoints: FACT-BL TOI (refer to as TOI), FACT-BL Total score, and NFBlSI-18 score.&#xD;
All the 5 subscales (PWB (0-28), FWB (0-28), EWB (0-24), SWB (0-28), and BlCS(0-48)) are summed as the FACT-BL total score (range 0-156), while the sum of PWB, FWB and BICS constitutes the FACT-BL TOI (range 0-104).&#xD;
NFBlSI-18 (range 0-72) is based on the scores of 16 items (GP4, C2, BL1, GP3, GE6, GE1, C6, BL5, GF5, GP2, GP1, GP6, C3, GP5, GF3, GF7) and 2 extra items &quot;I feel weak all overall&quot; and &quot;I feel light-headed (dizzy)&quot;. The range of each item is 0-4.&#xD;
Higher score represent worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</measure>
    <time_frame>At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>the change from baseline in the following total/index scores will be evaluated as secondary endpoints: FACT-BL TOI (refer to as TOI), FACT-BL Total score, and NFBlSI-18 score.&#xD;
All the 5 subscales (PWB (0-28), FWB (0-28), EWB (0-24), SWB (0-28), and BlCS(0-48)) are summed as the FACT-BL total score (range 0-156), while the sum of PWB, FWB and BICS constitutes the FACT-BL TOI (range 0-104).&#xD;
NFBlSI-18 (range 0-72) is based on the scores of 16 items (GP4, C2, BL1, GP3, GE6, GE1, C6, BL5, GF5, GP2, GP1, GP6, C3, GP5, GF3, GF7) and 2 extra items &quot;I feel weak all overall&quot; and &quot;I feel light-headed (dizzy)&quot;. The range of each item is 0-4.&#xD;
Higher score represent worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Fatigue and Deterioration in Pain Per FACT-BL, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</measure>
    <time_frame>At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>Fatigue will be based on the question of &quot;I have a lack of energy&quot; and pain will be based on the question of &quot;I have pain&quot;, according to GP1 and GP4 in PWB, respectively.&#xD;
Improvement in fatigue is defined at least 1 point improvement from baseline using GP1 of FACT-BL.&#xD;
Deterioration in pain is defined as at least 1 point deterioration from baseline using GP4 of FACT-BL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Fatigue and Deterioration in Pain Per FACT-BL, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</measure>
    <time_frame>At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>Fatigue will be based on the question of &quot;I have a lack of energy&quot; and pain will be based on the question of &quot;I have pain&quot;, according to GP1 and GP4 in PWB, respectively.&#xD;
Improvement in fatigue is defined at least 1 point improvement from baseline using GP1 of FACT-BL.&#xD;
Deterioration in pain is defined as at least 1 point deterioration from baseline using GP4 of FACT-BL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Fatigue and Deterioration in Pain Per FACT-BL, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</measure>
    <time_frame>At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
    <description>Fatigue will be based on the question of &quot;I have a lack of energy&quot; and pain will be based on the question of &quot;I have pain&quot;, according to GP1 and GP4 in PWB, respectively.&#xD;
Improvement in fatigue is defined at least 1 point improvement from baseline using GP1 of FACT-BL.&#xD;
Deterioration in pain is defined as at least 1 point deterioration from baseline using GP4 of FACT-BL.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1126</enrollment>
  <condition>Urothelial Cancer</condition>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI4736 (Durvalumab)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care Chemotherapy Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI4736 (Durvalumab)</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically or cytologically documented, unresectable, Stage IV&#xD;
             transitional cell carcinoma of the urothelium who have not been previously treated&#xD;
             with first-line chemotherapy.&#xD;
&#xD;
          -  Patients eligible or ineligible for cisplatin-based chemotherapy. Cisplatin&#xD;
             ineligibility is defined as meeting 1 of the following criteria: ‚Ä¢ Creatinine&#xD;
             clearance (calculated or measured) &lt;60 mL/min calculated by Cockcroft-Gault equation&#xD;
             (using actual body weight) or by measured 24-hour urine collection for determination ‚Ä¢&#xD;
             Common Terminology Criteria for Adverse Events (CTCAE) Grade ‚â•2 audiometric hearing&#xD;
             loss ‚Ä¢ CTCAE Grade ‚â•2 peripheral neuropathy ‚Ä¢ New York Heart Association ‚â•Class III&#xD;
             heart failure.&#xD;
&#xD;
          -  Tumor PD-L1 status, with Immunohistochemical (IHC) assay confirmed by a reference&#xD;
             laboratory, must be known prior to randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to immune-mediated therapy, including but not limited to, other anti&#xD;
             cytotoxic T-lymphocyte-associated protein 4 (CTLA 4), anti-PD-1, anti-PD-L1, or&#xD;
             anti-PD-L2 antibodies, including therapeutic anticancer vaccines. Prior local&#xD;
             intervesical chemotherapy or immunotherapy is allowed if completed at least 28 days&#xD;
             prior to the initiation of study treatment.&#xD;
&#xD;
          -  History of allogenic organ transplantation that requires use of immunosuppressive&#xD;
             agents.&#xD;
&#xD;
          -  Active or prior documented autoimmune or inflammatory disorders. The following are&#xD;
             exceptions to this criterion: ‚Ä¢ Patients with vitiligo or alopecia ‚Ä¢ Patients with&#xD;
             hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement ‚Ä¢ Any&#xD;
             chronic skin condition that does not require systemic therapy ‚Ä¢ Patients without&#xD;
             active disease in the last 3 years may be included but only after consultation with&#xD;
             AstraZeneca ‚Ä¢ Patients with celiac disease controlled by diet alone may be included&#xD;
             but only after consultation with AstraZeneca.&#xD;
&#xD;
          -  Brain metastases or spinal cord compression unless the patient's condition is stable&#xD;
             and off steroids for at least 14 days prior to the start of study treatment. Patients&#xD;
             with suspected or known brain metastases at screening should have an MRI&#xD;
             (preferred)/CT, preferably with IV contrast to access baseline disease status.&#xD;
&#xD;
          -  Active infection including tuberculosis, hepatitis B, hepatitis C, or human&#xD;
             immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 14 days before the first&#xD;
             dose of investigational product (IP). The following are exceptions to this criterion:&#xD;
             ‚Ä¢ Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra&#xD;
             articular injection) ‚Ä¢ Systemic corticosteroids at physiologic doses not to exceed 10&#xD;
             mg/day of prednisone or its equivalent ‚Ä¢ Steroids as premedication for&#xD;
             hypersensitivity reactions (eg, CT scan premedication).&#xD;
&#xD;
          -  Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note:&#xD;
             Patients, if enrolled, should not receive live vaccine during the study and up to 30&#xD;
             days after the last dose of IP.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Box Hill</city>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elizabeth Vale</city>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Macquarie University</city>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Leonards</city>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waratah</city>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Li√®ge</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barretos</city>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30380-472</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ijui</city>
        <zip>98700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Itajai</city>
        <zip>88310-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20231-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22793-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01209-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01321-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01509-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>S√£o Jos√© do Rio Preto</city>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 3S1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changchun</city>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>ChongQing</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenyang</city>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300211</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xiamen</city>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>K√∏benhavn √ò</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>√Örhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caen Cedex</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille cedex 09</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poitiers Cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suresnes Cedex</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>D√ºsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>M√ºnchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>M√ºnster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heraklion</city>
        <zip>711 11</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Holargos, Athens</city>
        <zip>155 62</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaliftaki, N.Kifissia, Athens</city>
        <zip>14564</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maroussi, Athens</city>
        <zip>15125</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56 429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arezzo</city>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Akita-shi</city>
        <zip>010-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <zip>811-1347</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hakata-shi</city>
        <zip>812-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hirosaki-shi</city>
        <zip>036-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hiroshima-shi</city>
        <zip>730-8518</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izumo-shi</city>
        <zip>693-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kagoshima-shi</city>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kanazawa-shi</city>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kita-gun</city>
        <zip>761-0793</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobe-shi</city>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koshigaya-shi</city>
        <zip>343-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koto-ku</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kumamoto-shi</city>
        <zip>860-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsuyama-shi</city>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morioka-shi</city>
        <zip>028-3695</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagasaki-shi</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osakasayama-shi</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saga-shi</city>
        <zip>840-8571</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sagamihara-shi</city>
        <zip>252-0315</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sakura-shi</city>
        <zip>285-8741</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suita-shi</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takatsuki-shi</city>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Le√≥n</city>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico, D.F</city>
        <zip>01120</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico</city>
        <zip>06760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>M√©xico</city>
        <zip>04739</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Breda</city>
        <zip>4819 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Enschede</city>
        <zip>7512 KZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gda≈Ñsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gda≈Ñsk</city>
        <zip>80-462</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gliwice</city>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Otwock</city>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Loures</city>
        <zip>2674-514</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Murmansk</city>
        <zip>183047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhnyi Novgorod</city>
        <zip>603001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>199178</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St.Petersburg</city>
        <zip>191014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ufa</city>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Badajoz</city>
        <zip>06008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elche(Alicante)</city>
        <zip>03202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>00407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cardiff.</city>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wirral</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D419BC00001&amp;amp;attachmentIdentifier=bfebc14d-a0f4-45b7-89cb-4a165e27074b&amp;amp;fileName=D419BC00001_SAPv5-redacted.pdf&amp;amp;versionIdentifier=</url>
    <description>Redacted SAP</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D419BC00001&amp;amp;attachmentIdentifier=a04d44be-8078-4bc2-9423-9816fa57e99d&amp;amp;fileName=d419bc00001-CSP-v9-redacted.pdf&amp;amp;versionIdentifier=</url>
    <description>Redacted Protocol</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 13, 2015</study_first_submitted>
  <study_first_submitted_qc>August 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2015</study_first_posted>
  <results_first_submitted>January 25, 2021</results_first_submitted>
  <results_first_submitted_qc>April 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 13, 2021</results_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urothelial Cancer</keyword>
  <keyword>Phase III</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02516241/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02516241/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combination Therapy</title>
          <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
        </group>
        <group group_id="P2">
          <title>Monotherapy</title>
          <description>MEDI4736 (Durvalumab)</description>
        </group>
        <group group_id="P3">
          <title>Standard of Care</title>
          <description>Standard of Care Chemotherapy Treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="342"/>
                <participants group_id="P2" count="346"/>
                <participants group_id="P3" count="344"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="340"/>
                <participants group_id="P2" count="345"/>
                <participants group_id="P3" count="313"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="342"/>
                <participants group_id="P2" count="346"/>
                <participants group_id="P3" count="344"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="255"/>
                <participants group_id="P2" count="262"/>
                <participants group_id="P3" count="270"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>participants ongoing at data cut-off</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="59"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
      <group_list>
        <group group_id="B1">
          <title>Combination Therapy</title>
          <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
        </group>
        <group group_id="B2">
          <title>Monotherapy</title>
          <description>MEDI4736 (Durvalumab)</description>
        </group>
        <group group_id="B3">
          <title>Standard of Care</title>
          <description>Standard of Care Chemotherapy Treatment</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="342"/>
            <count group_id="B2" value="346"/>
            <count group_id="B3" value="344"/>
            <count group_id="B4" value="1032"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age (years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.4" spread="9.60"/>
                    <measurement group_id="B2" value="66.3" spread="9.9"/>
                    <measurement group_id="B3" value="67.0" spread="9.32"/>
                    <measurement group_id="B4" value="66.5" spread="9.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age Group (Years)</title>
              <category_list>
                <category>
                  <title>&lt;50</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 50 - &lt; 65</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="119"/>
                    <measurement group_id="B4" value="352"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 65 - &lt; 75</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="137"/>
                    <measurement group_id="B4" value="410"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 75</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Sex</title>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="253"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="256"/>
                    <measurement group_id="B2" value="249"/>
                    <measurement group_id="B3" value="274"/>
                    <measurement group_id="B4" value="779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="320"/>
                    <measurement group_id="B2" value="329"/>
                    <measurement group_id="B3" value="322"/>
                    <measurement group_id="B4" value="971"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="253"/>
                    <measurement group_id="B2" value="278"/>
                    <measurement group_id="B3" value="260"/>
                    <measurement group_id="B4" value="791"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="208"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or other Pacific islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis Set</title>
        <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
        <time_frame>From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis Set</title>
          <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
          <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" lower_limit="13.1" upper_limit="18.0"/>
                    <measurement group_id="O2" value="12.1" lower_limit="10.9" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0751</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>98.66</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.688</ci_lower_limit>
            <ci_upper_limit>1.063</ci_upper_limit>
            <estimate_desc>The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Assess the Efficacy of Durvalumab Monotherapy Versus SoC in Terms of OS in PD-L1-High Analysis Set</title>
        <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
        <time_frame>From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
        <group_list>
          <group group_id="O1">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Efficacy of Durvalumab Monotherapy Versus SoC in Terms of OS in PD-L1-High Analysis Set</title>
          <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
          <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" lower_limit="10.4" upper_limit="17.3"/>
                    <measurement group_id="O2" value="12.1" lower_limit="10.4" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3039</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>96.99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.695</ci_lower_limit>
            <ci_upper_limit>1.139</ci_upper_limit>
            <estimate_desc>The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS, Full Analysis Set - Durvalumab Monotherapy vs SoC</title>
        <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
        <time_frame>From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>OS, Full Analysis Set - Durvalumab Monotherapy vs SoC</title>
          <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
          <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" lower_limit="10.3" upper_limit="15"/>
                    <measurement group_id="O2" value="12.1" lower_limit="10.9" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8637</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.830</ci_lower_limit>
            <ci_upper_limit>1.169</ci_upper_limit>
            <estimate_desc>The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC</title>
        <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
        <time_frame>From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>OS, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC</title>
          <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
          <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" lower_limit="14.8" upper_limit="24.2"/>
                    <measurement group_id="O2" value="12.1" lower_limit="10.4" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0091</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.589</ci_lower_limit>
            <ci_upper_limit>0.928</ci_upper_limit>
            <estimate_desc>The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy</title>
        <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
        <time_frame>From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>OS, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy</title>
          <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
          <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="8.9" upper_limit="15.8"/>
                    <measurement group_id="O2" value="10.9" lower_limit="8.0" upper_limit="14.8"/>
                    <measurement group_id="O3" value="12.2" lower_limit="10.4" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7599</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.799</ci_lower_limit>
            <ci_upper_limit>1.359</ci_upper_limit>
            <estimate_desc>The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>monotherapy as reference.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4424</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.692</ci_lower_limit>
            <ci_upper_limit>1.175</ci_upper_limit>
            <estimate_desc>The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alive at 24 Months (OS24), Full Analysis Set</title>
        <description>Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months.</description>
        <time_frame>From randomization date until death due to any cause, assessed up to 24 months or the data cut-off date (27JAN2020).</time_frame>
        <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Alive at 24 Months (OS24), Full Analysis Set</title>
          <description>Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months.</description>
          <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="346"/>
                <count group_id="O3" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" lower_limit="33.8" upper_limit="44.2"/>
                    <measurement group_id="O2" value="31.5" lower_limit="26.6" upper_limit="36.4"/>
                    <measurement group_id="O3" value="29.0" lower_limit="24.2" upper_limit="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alive at 24 Months (OS24), PD-L1-High Analysis Set</title>
        <description>Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months.</description>
        <time_frame>From randomization date until death due to any cause, assessed up to 24 months or the data cut-off date (27JAN2020).</time_frame>
        <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Alive at 24 Months (OS24), PD-L1-High Analysis Set</title>
          <description>Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months.</description>
          <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7" lower_limit="36.8" upper_limit="50.3"/>
                    <measurement group_id="O2" value="36.0" lower_limit="29.5" upper_limit="42.6"/>
                    <measurement group_id="O3" value="29.3" lower_limit="23.1" upper_limit="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alive at 24 Months (OS24), PD-L1-Low/Negative Analysis Set</title>
        <description>Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months.</description>
        <time_frame>From randomization date until death due to any cause, assessed up to 24 months or the data cut-off date (27JAN2020).</time_frame>
        <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Alive at 24 Months (OS24), PD-L1-Low/Negative Analysis Set</title>
          <description>Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months.</description>
          <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1" lower_limit="24.5" upper_limit="40.0"/>
                    <measurement group_id="O2" value="24.5" lower_limit="17.6" upper_limit="32.0"/>
                    <measurement group_id="O3" value="28.6" lower_limit="21.2" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
        <description>Progression free survival (PFS) (per RECIST 1.1, as assessed by investigator) was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to progression.&#xD;
Median PFS was calculated using the Kaplan-Meier technique.</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>PFS, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
          <description>Progression free survival (PFS) (per RECIST 1.1, as assessed by investigator) was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to progression.&#xD;
Median PFS was calculated using the Kaplan-Meier technique.</description>
          <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="346"/>
                <count group_id="O3" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="3.4" upper_limit="3.8"/>
                    <measurement group_id="O2" value="2.3" lower_limit="1.9" upper_limit="3.5"/>
                    <measurement group_id="O3" value="6.7" lower_limit="5.7" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2579</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.931</ci_lower_limit>
            <ci_upper_limit>1.304</ci_upper_limit>
            <estimate_desc>The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0008</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.124</ci_lower_limit>
            <ci_upper_limit>1.567</ci_upper_limit>
            <estimate_desc>The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC</title>
        <description>Progression free survival (PFS) (per RECIST 1.1, as assessed by investigator) was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to progression.&#xD;
Median PFS was calculated using the Kaplan-Meier technique.</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>PFS, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC</title>
          <description>Progression free survival (PFS) (per RECIST 1.1, as assessed by investigator) was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to progression.&#xD;
Median PFS was calculated using the Kaplan-Meier technique.</description>
          <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="3.6" upper_limit="5.7"/>
                    <measurement group_id="O2" value="2.4" lower_limit="1.9" upper_limit="3.7"/>
                    <measurement group_id="O3" value="5.8" lower_limit="5.6" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2395</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.705</ci_lower_limit>
            <ci_upper_limit>1.091</ci_upper_limit>
            <estimate_desc>The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2431</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.917</ci_lower_limit>
            <ci_upper_limit>1.406</ci_upper_limit>
            <estimate_desc>The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy</title>
        <description>Progression free survival (PFS) (per RECIST 1.1, as assessed by investigator) was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to progression.&#xD;
Median PFS was calculated using the Kaplan-Meier technique.</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>PFS, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy</title>
          <description>Progression free survival (PFS) (per RECIST 1.1, as assessed by investigator) was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to progression.&#xD;
Median PFS was calculated using the Kaplan-Meier technique.</description>
          <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.9" upper_limit="3.6"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.9" upper_limit="3.5"/>
                    <measurement group_id="O3" value="7.2" lower_limit="5.7" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0014</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.177</ci_lower_limit>
            <ci_upper_limit>1.990</ci_upper_limit>
            <estimate_desc>The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>monotherapy as reference.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6236</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.729</ci_lower_limit>
            <ci_upper_limit>1.209</ci_upper_limit>
            <estimate_desc>The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alive and Progression-free at 12 Months (APF12), Full Analysis Set</title>
        <description>Alive and progression-free at 12 months (APF12) was defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by investigator) at 12 months.</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).</time_frame>
        <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Alive and Progression-free at 12 Months (APF12), Full Analysis Set</title>
          <description>Alive and progression-free at 12 months (APF12) was defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by investigator) at 12 months.</description>
          <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="346"/>
                <count group_id="O3" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="17.2" upper_limit="26.0"/>
                    <measurement group_id="O2" value="16.8" lower_limit="13.1" upper_limit="21.1"/>
                    <measurement group_id="O3" value="15.3" lower_limit="11.4" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alive and Progression-free at 12 Months (APF12), PD-L1-High Analysis Set</title>
        <description>Alive and progression-free at 12 months (APF12) was defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by investigator) at 12 months.</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).</time_frame>
        <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Alive and Progression-free at 12 Months (APF12), PD-L1-High Analysis Set</title>
          <description>Alive and progression-free at 12 months (APF12) was defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by investigator) at 12 months.</description>
          <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" lower_limit="19.7" upper_limit="31.8"/>
                    <measurement group_id="O2" value="21.2" lower_limit="15.9" upper_limit="27.0"/>
                    <measurement group_id="O3" value="15.0" lower_limit="10.2" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alive and Progression-free at 12 Months (APF12), PD-L1-Low/Negative Analysis Set</title>
        <description>Alive and progression-free at 12 months (APF12) was defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by investigator) at 12 months.</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).</time_frame>
        <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Alive and Progression-free at 12 Months (APF12), PD-L1-Low/Negative Analysis Set</title>
          <description>Alive and progression-free at 12 months (APF12) was defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by investigator) at 12 months.</description>
          <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" lower_limit="9.6" upper_limit="21.8"/>
                    <measurement group_id="O2" value="9.7" lower_limit="5.4" upper_limit="15.7"/>
                    <measurement group_id="O3" value="15.6" lower_limit="9.6" upper_limit="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS2, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
        <description>Time from randomization to second progression or death (PFS2) was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy or death (ie, date of PFS2 event or censoring - date of randomization +1).&#xD;
Median PFS2 was calculated using the Kaplan-Meier technique.</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until first confirmed disease progression, disease then assessed per local practice until 2nd progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>PFS2, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
          <description>Time from randomization to second progression or death (PFS2) was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy or death (ie, date of PFS2 event or censoring - date of randomization +1).&#xD;
Median PFS2 was calculated using the Kaplan-Meier technique.</description>
          <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="346"/>
                <count group_id="O3" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="11.3" upper_limit="17.8"/>
                    <measurement group_id="O2" value="11.9" lower_limit="8.9" upper_limit="14.6"/>
                    <measurement group_id="O3" value="11.5" lower_limit="10.3" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0477</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.683</ci_lower_limit>
            <ci_upper_limit>0.998</ci_upper_limit>
            <estimate_desc>The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7885</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.809</ci_lower_limit>
            <ci_upper_limit>1.175</ci_upper_limit>
            <estimate_desc>The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS2, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC</title>
        <description>Time from randomization to second progression or death (PFS2) was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy or death (ie, date of PFS2 event or censoring - date of randomization +1).&#xD;
Median PFS2 was calculated using the Kaplan-Meier technique.</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until first confirmed disease progression, disease then assessed per local practice until 2nd progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>PFS2, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC</title>
          <description>Time from randomization to second progression or death (PFS2) was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy or death (ie, date of PFS2 event or censoring - date of randomization +1).&#xD;
Median PFS2 was calculated using the Kaplan-Meier technique.</description>
          <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" lower_limit="12.1" upper_limit="24.8"/>
                    <measurement group_id="O2" value="13.4" lower_limit="9.7" upper_limit="17.5"/>
                    <measurement group_id="O3" value="11.3" lower_limit="8.9" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0053</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.549</ci_lower_limit>
            <ci_upper_limit>0.901</ci_upper_limit>
            <estimate_desc>The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1336</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.651</ci_lower_limit>
            <ci_upper_limit>1.059</ci_upper_limit>
            <estimate_desc>The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS2, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy</title>
        <description>Time from randomization to second progression or death (PFS2) was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy or death (ie, date of PFS2 event or censoring - date of randomization +1).&#xD;
Median PFS2 was calculated using the Kaplan-Meier technique.</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until first confirmed disease progression, disease then assessed per local practice until 2nd progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>PFS2, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy</title>
          <description>Time from randomization to second progression or death (PFS2) was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy or death (ie, date of PFS2 event or censoring - date of randomization +1).&#xD;
Median PFS2 was calculated using the Kaplan-Meier technique.</description>
          <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" lower_limit="7.5" upper_limit="16.6"/>
                    <measurement group_id="O2" value="9.4" lower_limit="7.0" upper_limit="13.7"/>
                    <measurement group_id="O3" value="11.6" lower_limit="10.3" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8148</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.772</ci_lower_limit>
            <ci_upper_limit>1.391</ci_upper_limit>
            <estimate_desc>The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>monotherapy as reference.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2684</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.636</ci_lower_limit>
            <ci_upper_limit>1.134</ci_upper_limit>
            <estimate_desc>The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for visceral metastases and cisplatin eligibility status with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR), Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
        <description>Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR), Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
          <description>Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.</description>
          <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="346"/>
                <count group_id="O3" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3"/>
                    <measurement group_id="O2" value="25.7"/>
                    <measurement group_id="O3" value="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.422</ci_lower_limit>
            <ci_upper_limit>0.788</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.253</ci_lower_limit>
            <ci_upper_limit>0.485</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR), PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC</title>
        <description>Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR), PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC</title>
          <description>Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.</description>
          <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.8"/>
                    <measurement group_id="O2" value="27.8"/>
                    <measurement group_id="O3" value="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7708</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.639</ci_lower_limit>
            <ci_upper_limit>1.394</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.268</ci_lower_limit>
            <ci_upper_limit>0.610</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR), PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy</title>
        <description>Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR), PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy</title>
          <description>Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.</description>
          <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4"/>
                    <measurement group_id="O2" value="22.6"/>
                    <measurement group_id="O3" value="50.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.135</ci_lower_limit>
            <ci_upper_limit>0.406</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>monotherapy as reference.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6195</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.469</ci_lower_limit>
            <ci_upper_limit>1.566</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR) Based on BICR Assessment According to RECIST 1.1 - Responses Are Confirmed - Durvalumab Cisplatin Ineligible Population</title>
        <description>Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.&#xD;
unconfirmed responses are excluded.</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (01NOV2017, a maximum of 3 years).</time_frame>
        <population>Durvalumab Cisplatin Ineligible Population include all patients who had received D monotherapy and were not eligible for cisplatin treatment at baseline (per eCRF).</population>
        <group_list>
          <group group_id="O1">
            <title>Monotherapy - PD-L1 High</title>
            <description>MEDI4736 (Durvalumab) - PD-L1 high</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy - PD-L1 Low/Negative</title>
            <description>MEDI4736 (Durvalumab) - PD-L1 low/negative</description>
          </group>
          <group group_id="O3">
            <title>Monotherapy - Total</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) Based on BICR Assessment According to RECIST 1.1 - Responses Are Confirmed - Durvalumab Cisplatin Ineligible Population</title>
          <description>Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.&#xD;
unconfirmed responses are excluded.</description>
          <population>Durvalumab Cisplatin Ineligible Population include all patients who had received D monotherapy and were not eligible for cisplatin treatment at baseline (per eCRF).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR) at 6 Months, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
        <description>Disease control rate (DCR) at 6 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 24 weeks (-7 days, i.e., 161 days), following the start of study treatment.</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 6 months or the data cut-off date (27JAN2020).</time_frame>
        <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR) at 6 Months, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
          <description>Disease control rate (DCR) at 6 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 24 weeks (-7 days, i.e., 161 days), following the start of study treatment.</description>
          <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="346"/>
                <count group_id="O3" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.5"/>
                    <measurement group_id="O2" value="31.8"/>
                    <measurement group_id="O3" value="55.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.410</ci_lower_limit>
            <ci_upper_limit>0.759</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.267</ci_lower_limit>
            <ci_upper_limit>0.500</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR) at 6 Months, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC</title>
        <description>Disease control rate (DCR) at 6 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 24 weeks (-7 days, i.e., 161 days), following the start of study treatment.</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 6 months or the data cut-off date (27JAN2020).</time_frame>
        <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR) at 6 Months, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC</title>
          <description>Disease control rate (DCR) at 6 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 24 weeks (-7 days, i.e., 161 days), following the start of study treatment.</description>
          <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8"/>
                    <measurement group_id="O2" value="34.4"/>
                    <measurement group_id="O3" value="53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4959</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.590</ci_lower_limit>
            <ci_upper_limit>1.291</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.305</ci_lower_limit>
            <ci_upper_limit>0.679</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR) at 6 Months, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy</title>
        <description>Disease control rate (DCR) at 6 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 24 weeks (-7 days, i.e., 161 days), following the start of study treatment.</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 6 months or the data cut-off date (27JAN2020).</time_frame>
        <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR) at 6 Months, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy</title>
          <description>Disease control rate (DCR) at 6 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 24 weeks (-7 days, i.e., 161 days), following the start of study treatment.</description>
          <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2"/>
                    <measurement group_id="O2" value="27.7"/>
                    <measurement group_id="O3" value="59.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.160</ci_lower_limit>
            <ci_upper_limit>0.448</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>monotherapy as reference.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8074</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.623</ci_lower_limit>
            <ci_upper_limit>1.836</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR) at 12 Months, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
        <description>Disease control rate (DCR) at 12 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 48 weeks (-7 days, i.e., 329 days), following the start of study treatment.</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020)</time_frame>
        <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR) at 12 Months, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
          <description>Disease control rate (DCR) at 12 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 48 weeks (-7 days, i.e., 329 days), following the start of study treatment.</description>
          <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="346"/>
                <count group_id="O3" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0"/>
                    <measurement group_id="O2" value="28.0"/>
                    <measurement group_id="O3" value="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0008</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.432</ci_lower_limit>
            <ci_upper_limit>0.802</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.270</ci_lower_limit>
            <ci_upper_limit>0.512</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR) at 12 Months, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC</title>
        <description>Disease control rate (DCR) at 12 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 48 weeks (-7 days, i.e., 329 days), following the start of study treatment.</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).</time_frame>
        <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR) at 12 Months, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC</title>
          <description>Disease control rate (DCR) at 12 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 48 weeks (-7 days, i.e., 329 days), following the start of study treatment.</description>
          <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3"/>
                    <measurement group_id="O2" value="30.6"/>
                    <measurement group_id="O3" value="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7717</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.639</ci_lower_limit>
            <ci_upper_limit>1.394</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.303</ci_lower_limit>
            <ci_upper_limit>0.682</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR) at 12 Months, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy</title>
        <description>Disease control rate (DCR) at 12 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 48 weeks (-7 days, i.e., 329 days), following the start of study treatment.</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).</time_frame>
        <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR) at 12 Months, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy</title>
          <description>Disease control rate (DCR) at 12 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 48 weeks (-7 days, i.e., 329 days), following the start of study treatment.</description>
          <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1"/>
                    <measurement group_id="O2" value="24.1"/>
                    <measurement group_id="O3" value="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.151</ci_lower_limit>
            <ci_upper_limit>0.439</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>monotherapy as reference.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9692</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.556</ci_lower_limit>
            <ci_upper_limit>1.759</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DoR), Full Analysis Set</title>
        <description>Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1).</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DoR), Full Analysis Set</title>
          <description>Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1).</description>
          <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="346"/>
                <count group_id="O3" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="4.3" upper_limit="NA">upper limit is not reached</measurement>
                    <measurement group_id="O2" value="9.3" lower_limit="5.4" upper_limit="NA">upper limit is not reached</measurement>
                    <measurement group_id="O3" value="5.7" lower_limit="3.7" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DoR), PD-L1-High Analysis Set</title>
        <description>Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1).</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DoR), PD-L1-High Analysis Set</title>
          <description>Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1).</description>
          <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="3.8" upper_limit="NA">upper limit is not reached.</measurement>
                    <measurement group_id="O2" value="18.5" lower_limit="5.6" upper_limit="NA">upper limit is not reached.</measurement>
                    <measurement group_id="O3" value="5.8" lower_limit="3.7" upper_limit="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DoR), PD-L1-Low/Negative Analysis Set</title>
        <description>Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1).</description>
        <time_frame>Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DoR), PD-L1-Low/Negative Analysis Set</title>
          <description>Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1).</description>
          <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" lower_limit="5.5" upper_limit="NA">upper limit is not reached.</measurement>
                    <measurement group_id="O2" value="5.6" lower_limit="3.8" upper_limit="NA">upper limit is not reached.</measurement>
                    <measurement group_id="O3" value="5.7" lower_limit="3.9" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentrations of Durvalumab, Pharmacokinetic Analysis Set</title>
        <description>Blood samples were collected to determine the serum concentration of durvalumab.</description>
        <time_frame>Pre-dose and within 1 hour after end of infusion at Week 0, 12 and 24, pre-dose at week 4, and at follow-up Month 3.</time_frame>
        <population>Pharmacokinetic analysis set included all patients who received at least 1 dose of durvalumab or tremelimumab per the protocol and had at least one post dose evaluable PK data of durvalumab or tremelimumab</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentrations of Durvalumab, Pharmacokinetic Analysis Set</title>
          <description>Blood samples were collected to determine the serum concentration of durvalumab.</description>
          <population>Pharmacokinetic analysis set included all patients who received at least 1 dose of durvalumab or tremelimumab per the protocol and had at least one post dose evaluable PK data of durvalumab or tremelimumab</population>
          <units>Œºg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 - Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="329"/>
                    <count group_id="O2" value="339"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">week 0 pre-dose serum concentrations are below the level of detection</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">week 0 pre-dose serum concentrations are below the level of detection</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 - Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="328"/>
                    <count group_id="O2" value="334"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="511" spread="338"/>
                    <measurement group_id="O2" value="484" spread="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="285"/>
                    <count group_id="O2" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3" spread="84.4"/>
                    <measurement group_id="O2" value="78.9" spread="56.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125" spread="97.7"/>
                    <measurement group_id="O2" value="144" spread="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="186"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="594" spread="298"/>
                    <measurement group_id="O2" value="576" spread="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150" spread="94.4"/>
                    <measurement group_id="O2" value="163" spread="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="604" spread="249"/>
                    <measurement group_id="O2" value="600" spread="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" spread="50"/>
                    <measurement group_id="O2" value="19.9" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentrations of Tremelimumab, Pharmacokinetic Analysis Set</title>
        <description>Blood samples were collected to determine the serum concentration of tremelimumab.</description>
        <time_frame>Pre-dose and within 1 hour after end of infusion at Week 0, 12 and 24, pre-dose at week 4, and at follow-up Month 3.</time_frame>
        <population>Pharmacokinetic analysis set included all patients who received at least 1 dose of durvalumab or tremelimumab per the protocol and had at least one post dose evaluable PK data of durvalumab or tremelimumab</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentrations of Tremelimumab, Pharmacokinetic Analysis Set</title>
          <description>Blood samples were collected to determine the serum concentration of tremelimumab.</description>
          <population>Pharmacokinetic analysis set included all patients who received at least 1 dose of durvalumab or tremelimumab per the protocol and had at least one post dose evaluable PK data of durvalumab or tremelimumab</population>
          <units>Œºg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 - Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">week 0 pre-dose serum concentrations are below the level of detection</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 - Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" spread="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.43" spread="4.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - Postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.943" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab, Safety Analysis Set - ADA Evaluable Patients</title>
        <description>Serum Samples will be measured for the presence of ADAs and ADA-neutralizing antibodies for Durvalumab using validated assays. Tiered analysis will be performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-na√Øve validation samples will be used. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The category may include patients meeting these criteria who are ADA positive at baseline.</description>
        <time_frame>At week 0, 4, 12 and 24, and at follow-up Month 3.</time_frame>
        <population>ADA evaluable patients is defined as patients in the safety analysis set who have a non-missing baseline ADA and at least one non-missing post-baseline result</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab, Safety Analysis Set - ADA Evaluable Patients</title>
          <description>Serum Samples will be measured for the presence of ADAs and ADA-neutralizing antibodies for Durvalumab using validated assays. Tiered analysis will be performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-na√Øve validation samples will be used. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The category may include patients meeting these criteria who are ADA positive at baseline.</description>
          <population>ADA evaluable patients is defined as patients in the safety analysis set who have a non-missing baseline ADA and at least one non-missing post-baseline result</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA evaluable patients</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="340"/>
                    <count group_id="O2" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293"/>
                    <measurement group_id="O2" value="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA positive at any visit (ADA Prevalence)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="293"/>
                    <count group_id="O2" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-emergent ADA positive (ADA Incidence)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="293"/>
                    <count group_id="O2" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-boosted ADA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="293"/>
                    <count group_id="O2" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-induced ADA (Positive Post-baseline only)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="293"/>
                    <count group_id="O2" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA Positive at Baseline only</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="293"/>
                    <count group_id="O2" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA Positive Post-baseline and Positive at Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="293"/>
                    <count group_id="O2" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistently Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="293"/>
                    <count group_id="O2" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transiently Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="293"/>
                    <count group_id="O2" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nAb Positive at any visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="293"/>
                    <count group_id="O2" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti-Drug Antibody (ADA) Response to Tremelimumab, Safety Analysis Set - ADA Evaluable Patients</title>
        <description>Serum Samples will be measured for the presence of ADAs and ADA-neutralizing antibodies for Tremelimumab using validated assays. Tiered analysis will be performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-na√Øve validation samples will be used. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The category may include patients meeting these criteria who are ADA positive at baseline.</description>
        <time_frame>At week 0, 4, 12 and at follow-up Month 3.</time_frame>
        <population>ADA evaluable patients is defined as patients in the safety analysis set who have a non-missing baseline ADA and at least one non-missing post-baseline result</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-Drug Antibody (ADA) Response to Tremelimumab, Safety Analysis Set - ADA Evaluable Patients</title>
          <description>Serum Samples will be measured for the presence of ADAs and ADA-neutralizing antibodies for Tremelimumab using validated assays. Tiered analysis will be performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-na√Øve validation samples will be used. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The category may include patients meeting these criteria who are ADA positive at baseline.</description>
          <population>ADA evaluable patients is defined as patients in the safety analysis set who have a non-missing baseline ADA and at least one non-missing post-baseline result</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA evaluable patients</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA positive at any visit (ADA Prevalence)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-emergent ADA positive (ADA Incidence)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-boosted ADA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-induced ADA (Positive Post-baseline only)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA Positive at Baseline only</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA Positive Post-baseline and Positive at Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistently Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transiently Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nAb Positive at any visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
        <description>the change from baseline in the following total/index scores will be evaluated as secondary endpoints: FACT-BL TOI (refer to as TOI), FACT-BL Total score, and NFBlSI-18 score.&#xD;
All the 5 subscales (PWB (0-28), FWB (0-28), EWB (0-24), SWB (0-28), and BlCS(0-48)) are summed as the FACT-BL total score (range 0-156), while the sum of PWB, FWB and BICS constitutes the FACT-BL TOI (range 0-104).&#xD;
NFBlSI-18 (range 0-72) is based on the scores of 16 items (GP4, C2, BL1, GP3, GE6, GE1, C6, BL5, GF5, GP2, GP1, GP6, C3, GP5, GF3, GF7) and 2 extra items &quot;I feel weak all overall&quot; and &quot;I feel light-headed (dizzy)&quot;. The range of each item is 0-4.&#xD;
Higher score represent worse outcome.</description>
        <time_frame>At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
          <description>the change from baseline in the following total/index scores will be evaluated as secondary endpoints: FACT-BL TOI (refer to as TOI), FACT-BL Total score, and NFBlSI-18 score.&#xD;
All the 5 subscales (PWB (0-28), FWB (0-28), EWB (0-24), SWB (0-28), and BlCS(0-48)) are summed as the FACT-BL total score (range 0-156), while the sum of PWB, FWB and BICS constitutes the FACT-BL TOI (range 0-104).&#xD;
NFBlSI-18 (range 0-72) is based on the scores of 16 items (GP4, C2, BL1, GP3, GE6, GE1, C6, BL5, GF5, GP2, GP1, GP6, C3, GP5, GF3, GF7) and 2 extra items &quot;I feel weak all overall&quot; and &quot;I feel light-headed (dizzy)&quot;. The range of each item is 0-4.&#xD;
Higher score represent worse outcome.</description>
          <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="346"/>
                <count group_id="O3" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NFBLSI - 18 Score (Average overall visits)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="220"/>
                    <count group_id="O2" value="204"/>
                    <count group_id="O3" value="189"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="0.70"/>
                    <measurement group_id="O2" value="-3.1" spread="0.76"/>
                    <measurement group_id="O3" value="-5.2" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACT-BL TOI (Average overall visits)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="220"/>
                    <count group_id="O2" value="204"/>
                    <count group_id="O3" value="189"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="0.87"/>
                    <measurement group_id="O2" value="-3.9" spread="0.95"/>
                    <measurement group_id="O3" value="-7.2" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACT-BL Total score (Average overall visits)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="220"/>
                    <count group_id="O2" value="204"/>
                    <count group_id="O3" value="189"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="1.19"/>
                    <measurement group_id="O2" value="-4.7" spread="1.30"/>
                    <measurement group_id="O3" value="-8.8" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>NFBLSI- 18 score (Average overall visits)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1617</p_value>
            <p_value_desc>MMRM model included patient, treatment, cisplatin eligibility, PD-L1 status and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>3.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>NFBLSI- 18 score (Average overall visits)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0578</p_value>
            <p_value_desc>MMRM model included patient, treatment, cisplatin eligibility, PD-L1 status and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>4.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>FACT-BL TOI (Average overall visits)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2003</p_value>
            <p_value_desc>MMRM model included patient, treatment, cisplatin eligibility, PD-L1 status and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>4.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>FACT-BL TOI (Average overall visits)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0178</p_value>
            <p_value_desc>MMRM model included patient, treatment, cisplatin eligibility, PD-L1 status and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>6.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>FACT-BL Total score (Average overall visits)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3765</p_value>
            <p_value_desc>MMRM model included patient, treatment, cisplatin eligibility, PD-L1 status and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.96</ci_lower_limit>
            <ci_upper_limit>5.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>FACT-BL Total score (Average overall visits)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0300</p_value>
            <p_value_desc>MMRM model included patient, treatment, cisplatin eligibility, PD-L1 status and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>7.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
        <description>the change from baseline in the following total/index scores will be evaluated as secondary endpoints: FACT-BL TOI (refer to as TOI), FACT-BL Total score, and NFBlSI-18 score.&#xD;
All the 5 subscales (PWB (0-28), FWB (0-28), EWB (0-24), SWB (0-28), and BlCS(0-48)) are summed as the FACT-BL total score (range 0-156), while the sum of PWB, FWB and BICS constitutes the FACT-BL TOI (range 0-104).&#xD;
NFBlSI-18 (range 0-72) is based on the scores of 16 items (GP4, C2, BL1, GP3, GE6, GE1, C6, BL5, GF5, GP2, GP1, GP6, C3, GP5, GF3, GF7) and 2 extra items &quot;I feel weak all overall&quot; and &quot;I feel light-headed (dizzy)&quot;. The range of each item is 0-4.&#xD;
Higher score represent worse</description>
        <time_frame>At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
          <description>the change from baseline in the following total/index scores will be evaluated as secondary endpoints: FACT-BL TOI (refer to as TOI), FACT-BL Total score, and NFBlSI-18 score.&#xD;
All the 5 subscales (PWB (0-28), FWB (0-28), EWB (0-24), SWB (0-28), and BlCS(0-48)) are summed as the FACT-BL total score (range 0-156), while the sum of PWB, FWB and BICS constitutes the FACT-BL TOI (range 0-104).&#xD;
NFBlSI-18 (range 0-72) is based on the scores of 16 items (GP4, C2, BL1, GP3, GE6, GE1, C6, BL5, GF5, GP2, GP1, GP6, C3, GP5, GF3, GF7) and 2 extra items &quot;I feel weak all overall&quot; and &quot;I feel light-headed (dizzy)&quot;. The range of each item is 0-4.&#xD;
Higher score represent worse</description>
          <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NFBLSI - 18 Score (Average overall visits)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="0.85"/>
                    <measurement group_id="O2" value="-2.0" spread="0.87"/>
                    <measurement group_id="O3" value="-5.7" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACT-BL TOI (Average overall visits)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="1.09"/>
                    <measurement group_id="O2" value="-2.6" spread="1.11"/>
                    <measurement group_id="O3" value="-8.0" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACT-BL Total score (Average overall visits)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="1.47"/>
                    <measurement group_id="O2" value="-2.7" spread="1.51"/>
                    <measurement group_id="O3" value="-10.1" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>NFBLSI- 18 score (Average overall visits)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1373</p_value>
            <p_value_desc>MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>4.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>NFBLSI- 18 score (Average overall visits)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0034</p_value>
            <p_value_desc>MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.26</ci_lower_limit>
            <ci_upper_limit>6.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>FACT-BL TOI (Average overall visits)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1774</p_value>
            <p_value_desc>MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>5.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>FACT-BL TOI (Average overall visits)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0011</p_value>
            <p_value_desc>MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.19</ci_lower_limit>
            <ci_upper_limit>8.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>FACT-BL Total score (Average overall visits)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3494</p_value>
            <p_value_desc>MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.27</ci_lower_limit>
            <ci_upper_limit>6.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>FACT-BL Total score (Average overall visits)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0011</p_value>
            <p_value_desc>MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.96</ci_lower_limit>
            <ci_upper_limit>11.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
        <description>the change from baseline in the following total/index scores will be evaluated as secondary endpoints: FACT-BL TOI (refer to as TOI), FACT-BL Total score, and NFBlSI-18 score.&#xD;
All the 5 subscales (PWB (0-28), FWB (0-28), EWB (0-24), SWB (0-28), and BlCS(0-48)) are summed as the FACT-BL total score (range 0-156), while the sum of PWB, FWB and BICS constitutes the FACT-BL TOI (range 0-104).&#xD;
NFBlSI-18 (range 0-72) is based on the scores of 16 items (GP4, C2, BL1, GP3, GE6, GE1, C6, BL5, GF5, GP2, GP1, GP6, C3, GP5, GF3, GF7) and 2 extra items &quot;I feel weak all overall&quot; and &quot;I feel light-headed (dizzy)&quot;. The range of each item is 0-4.&#xD;
Higher score represent worse</description>
        <time_frame>At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
          <description>the change from baseline in the following total/index scores will be evaluated as secondary endpoints: FACT-BL TOI (refer to as TOI), FACT-BL Total score, and NFBlSI-18 score.&#xD;
All the 5 subscales (PWB (0-28), FWB (0-28), EWB (0-24), SWB (0-28), and BlCS(0-48)) are summed as the FACT-BL total score (range 0-156), while the sum of PWB, FWB and BICS constitutes the FACT-BL TOI (range 0-104).&#xD;
NFBlSI-18 (range 0-72) is based on the scores of 16 items (GP4, C2, BL1, GP3, GE6, GE1, C6, BL5, GF5, GP2, GP1, GP6, C3, GP5, GF3, GF7) and 2 extra items &quot;I feel weak all overall&quot; and &quot;I feel light-headed (dizzy)&quot;. The range of each item is 0-4.&#xD;
Higher score represent worse</description>
          <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NFBLSI - 18 Score (Average overall visits)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="1.01"/>
                    <measurement group_id="O2" value="-3.8" spread="1.18"/>
                    <measurement group_id="O3" value="-2.0" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACT-BL TOI (Average overall visits)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="1.18"/>
                    <measurement group_id="O2" value="-5.0" spread="1.39"/>
                    <measurement group_id="O3" value="-3.0" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACT-BL Total score (Average overall visits)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="1.62"/>
                    <measurement group_id="O2" value="-6.5" spread="1.90"/>
                    <measurement group_id="O3" value="-3.2" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>NFBLSI- 18 score (Average overall visits)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3865</p_value>
            <p_value_desc>MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.35</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>NFBLSI- 18 score (Average overall visits)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2840</p_value>
            <p_value_desc>MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.05</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>FACT-BL TOI (Average overall visits)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2970</p_value>
            <p_value_desc>MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.41</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>FACT-BL TOI (Average overall visits)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3026</p_value>
            <p_value_desc>MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.85</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>FACT-BL Total score (Average overall visits)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3168</p_value>
            <p_value_desc>MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.29</ci_lower_limit>
            <ci_upper_limit>2.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>FACT-BL Total score (Average overall visits)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2179</p_value>
            <p_value_desc>MMRM model included patient, treatment, cisplatin eligibility and visceral metastasis, visit and treatment by visit interaction as explanatory variables, and the appropriate baseline FACT-BL value as a covariate.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.51</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in Fatigue and Deterioration in Pain Per FACT-BL, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
        <description>Fatigue will be based on the question of &quot;I have a lack of energy&quot; and pain will be based on the question of &quot;I have pain&quot;, according to GP1 and GP4 in PWB, respectively.&#xD;
Improvement in fatigue is defined at least 1 point improvement from baseline using GP1 of FACT-BL.&#xD;
Deterioration in pain is defined as at least 1 point deterioration from baseline using GP4 of FACT-BL.</description>
        <time_frame>At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Fatigue and Deterioration in Pain Per FACT-BL, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
          <description>Fatigue will be based on the question of &quot;I have a lack of energy&quot; and pain will be based on the question of &quot;I have pain&quot;, according to GP1 and GP4 in PWB, respectively.&#xD;
Improvement in fatigue is defined at least 1 point improvement from baseline using GP1 of FACT-BL.&#xD;
Deterioration in pain is defined as at least 1 point deterioration from baseline using GP4 of FACT-BL.</description>
          <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="346"/>
                <count group_id="O3" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with improvement in fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="129"/>
                    <count group_id="O3" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient with deterioration in pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="265"/>
                    <count group_id="O2" value="270"/>
                    <count group_id="O3" value="226"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="130"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patients with improvement in fatigue</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2419</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patients with improvement in fatigue</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1553</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patient with deterioration in pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patient with deterioration in pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0148</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for PD-L1 status, visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in Fatigue and Deterioration in Pain Per FACT-BL, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
        <description>Fatigue will be based on the question of &quot;I have a lack of energy&quot; and pain will be based on the question of &quot;I have pain&quot;, according to GP1 and GP4 in PWB, respectively.&#xD;
Improvement in fatigue is defined at least 1 point improvement from baseline using GP1 of FACT-BL.&#xD;
Deterioration in pain is defined as at least 1 point deterioration from baseline using GP4 of FACT-BL.</description>
        <time_frame>At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Fatigue and Deterioration in Pain Per FACT-BL, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
          <description>Fatigue will be based on the question of &quot;I have a lack of energy&quot; and pain will be based on the question of &quot;I have pain&quot;, according to GP1 and GP4 in PWB, respectively.&#xD;
Improvement in fatigue is defined at least 1 point improvement from baseline using GP1 of FACT-BL.&#xD;
Deterioration in pain is defined as at least 1 point deterioration from baseline using GP4 of FACT-BL.</description>
          <population>The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
‚â•25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ‚â•25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with improvement in fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient with deterioration in pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="156"/>
                    <count group_id="O2" value="164"/>
                    <count group_id="O3" value="145"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patients with improvement in fatigue</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2473</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patients with improvement in fatigue</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0148</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patient with deterioration in pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0090</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patient with deterioration in pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1510</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in Fatigue and Deterioration in Pain Per FACT-BL, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
        <description>Fatigue will be based on the question of &quot;I have a lack of energy&quot; and pain will be based on the question of &quot;I have pain&quot;, according to GP1 and GP4 in PWB, respectively.&#xD;
Improvement in fatigue is defined at least 1 point improvement from baseline using GP1 of FACT-BL.&#xD;
Deterioration in pain is defined as at least 1 point deterioration from baseline using GP4 of FACT-BL.</description>
        <time_frame>At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).</time_frame>
        <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>MEDI4736 (Durvalumab)</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care</title>
            <description>Standard of Care Chemotherapy Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Fatigue and Deterioration in Pain Per FACT-BL, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC</title>
          <description>Fatigue will be based on the question of &quot;I have a lack of energy&quot; and pain will be based on the question of &quot;I have pain&quot;, according to GP1 and GP4 in PWB, respectively.&#xD;
Improvement in fatigue is defined at least 1 point improvement from baseline using GP1 of FACT-BL.&#xD;
Deterioration in pain is defined as at least 1 point deterioration from baseline using GP4 of FACT-BL.</description>
          <population>The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:&#xD;
&lt;25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND &lt;25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with improvement in fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient with deterioration in pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patients with improvement in fatigue</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6763</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patients with improvement in fatigue</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6539</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patient with deterioration in pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0092</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patient with deterioration in pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0324</p_value>
            <p_value_desc>P-value was based on twice the change in log-likelihood resulting from logistic regression model, adjusting for visceral metastases and cisplatin eligibility status.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
            <estimate_desc>The OR and confidence interval (CI) were calculated using logistic regression, adjusting for visceral metastases and cisplatin eligibility status, with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first administration of study treatment up to 90 days after last dose of study medication or date of initiation of the first subsequent therapy, whichever occurs first, approximately 5 years. All-cause mortality, from screening up to data cut-off date (27JAN2020, approximately 5 years).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Combination Therapy</title>
          <description>MEDI4736 (Durvalumab) + Tremelimumab</description>
        </group>
        <group group_id="E2">
          <title>Monotherapy</title>
          <description>MEDI4736 (Durvalumab)</description>
        </group>
        <group group_id="E3">
          <title>Standard of Care</title>
          <description>Standard of Care Chemotherapy Treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="255" subjects_at_risk="342"/>
                <counts group_id="E2" subjects_affected="263" subjects_at_risk="346"/>
                <counts group_id="E3" subjects_affected="270" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="345"/>
                <counts group_id="E3" subjects_affected="125" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="345"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Haematotoxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Colonic fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="340"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Immune-mediated enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Extravasation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hernia pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="340"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="345"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hepatitis cholestatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Immune-mediated hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Amoebic dysentery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Listeriosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="340"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Prostatic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="345"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="345"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="26" subjects_affected="21" subjects_at_risk="340"/>
                <counts group_id="E2" events="23" subjects_affected="17" subjects_at_risk="345"/>
                <counts group_id="E3" events="28" subjects_affected="21" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="340"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Post procedural fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Radiation pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Stoma obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Urostomy complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hypercreatininaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Autoimmune arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Renal adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cerebral thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Immune-mediated neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Myasthenic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="340"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="345"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Bladder tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Obstructive nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Postrenal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="340"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Renal vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Urinary bladder rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Penile haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Penile pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diaphragmatic paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="340"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="340"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hypertensive urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="306" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="312" subjects_at_risk="345"/>
                <counts group_id="E3" subjects_affected="299" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="53" subjects_affected="51" subjects_at_risk="340"/>
                <counts group_id="E2" events="63" subjects_affected="58" subjects_at_risk="345"/>
                <counts group_id="E3" events="222" subjects_affected="163" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="50" subjects_affected="25" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="187" subjects_affected="89" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="345"/>
                <counts group_id="E3" events="64" subjects_affected="47" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="22" subjects_affected="19" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="340"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="345"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="34" subjects_affected="31" subjects_at_risk="340"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="345"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="47" subjects_affected="41" subjects_at_risk="340"/>
                <counts group_id="E2" events="50" subjects_affected="37" subjects_at_risk="345"/>
                <counts group_id="E3" events="31" subjects_affected="27" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="340"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="88" subjects_affected="79" subjects_at_risk="340"/>
                <counts group_id="E2" events="73" subjects_affected="66" subjects_at_risk="345"/>
                <counts group_id="E3" events="113" subjects_affected="89" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="146" subjects_affected="99" subjects_at_risk="340"/>
                <counts group_id="E2" events="96" subjects_affected="63" subjects_at_risk="345"/>
                <counts group_id="E3" events="78" subjects_affected="55" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="340"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="345"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="340"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="345"/>
                <counts group_id="E3" events="20" subjects_affected="18" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="65" subjects_affected="58" subjects_at_risk="340"/>
                <counts group_id="E2" events="88" subjects_affected="74" subjects_at_risk="345"/>
                <counts group_id="E3" events="237" subjects_affected="143" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="66" subjects_affected="56" subjects_at_risk="340"/>
                <counts group_id="E2" events="46" subjects_affected="36" subjects_at_risk="345"/>
                <counts group_id="E3" events="61" subjects_affected="48" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="69" subjects_affected="54" subjects_at_risk="340"/>
                <counts group_id="E2" events="49" subjects_affected="40" subjects_at_risk="345"/>
                <counts group_id="E3" events="106" subjects_affected="68" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="106" subjects_affected="89" subjects_at_risk="340"/>
                <counts group_id="E2" events="107" subjects_affected="98" subjects_at_risk="345"/>
                <counts group_id="E3" events="127" subjects_affected="101" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="340"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E3" events="21" subjects_affected="19" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="39" subjects_affected="30" subjects_at_risk="340"/>
                <counts group_id="E2" events="41" subjects_affected="36" subjects_at_risk="345"/>
                <counts group_id="E3" events="33" subjects_affected="27" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="80" subjects_affected="60" subjects_at_risk="340"/>
                <counts group_id="E2" events="66" subjects_affected="50" subjects_at_risk="345"/>
                <counts group_id="E3" events="63" subjects_affected="43" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="340"/>
                <counts group_id="E2" events="24" subjects_affected="18" subjects_at_risk="345"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="69" subjects_affected="54" subjects_at_risk="340"/>
                <counts group_id="E2" events="82" subjects_affected="58" subjects_at_risk="345"/>
                <counts group_id="E3" events="57" subjects_affected="46" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="340"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="345"/>
                <counts group_id="E3" events="24" subjects_affected="21" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="340"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="345"/>
                <counts group_id="E3" events="21" subjects_affected="16" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="340"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="345"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="25" subjects_affected="17" subjects_at_risk="340"/>
                <counts group_id="E2" events="33" subjects_affected="27" subjects_at_risk="345"/>
                <counts group_id="E3" events="37" subjects_affected="31" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="29" subjects_affected="23" subjects_at_risk="340"/>
                <counts group_id="E2" events="33" subjects_affected="18" subjects_at_risk="345"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E3" events="135" subjects_affected="55" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E3" events="124" subjects_affected="55" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="34" subjects_affected="33" subjects_at_risk="340"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="345"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E3" events="56" subjects_affected="29" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="79" subjects_affected="72" subjects_at_risk="340"/>
                <counts group_id="E2" events="74" subjects_affected="66" subjects_at_risk="345"/>
                <counts group_id="E3" events="102" subjects_affected="80" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="340"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="345"/>
                <counts group_id="E3" events="15" subjects_affected="10" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="340"/>
                <counts group_id="E2" events="24" subjects_affected="18" subjects_at_risk="345"/>
                <counts group_id="E3" events="27" subjects_affected="18" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="25" subjects_affected="21" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="56" subjects_affected="42" subjects_at_risk="340"/>
                <counts group_id="E2" events="45" subjects_affected="36" subjects_at_risk="345"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="38" subjects_affected="34" subjects_at_risk="340"/>
                <counts group_id="E2" events="46" subjects_affected="41" subjects_at_risk="345"/>
                <counts group_id="E3" events="34" subjects_affected="31" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="340"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="345"/>
                <counts group_id="E3" events="23" subjects_affected="22" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="30" subjects_affected="27" subjects_at_risk="340"/>
                <counts group_id="E2" events="21" subjects_affected="15" subjects_at_risk="345"/>
                <counts group_id="E3" events="32" subjects_affected="25" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="340"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="345"/>
                <counts group_id="E3" events="30" subjects_affected="26" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="28" subjects_affected="20" subjects_at_risk="340"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="345"/>
                <counts group_id="E3" events="19" subjects_affected="16" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="345"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="25" subjects_at_risk="340"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="345"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="40" subjects_affected="36" subjects_at_risk="340"/>
                <counts group_id="E2" events="48" subjects_affected="39" subjects_at_risk="345"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="55" subjects_affected="46" subjects_at_risk="340"/>
                <counts group_id="E2" events="41" subjects_affected="35" subjects_at_risk="345"/>
                <counts group_id="E3" events="20" subjects_affected="18" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="340"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="345"/>
                <counts group_id="E3" events="30" subjects_affected="27" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E3" events="33" subjects_affected="23" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="340"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="345"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="340"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E3" events="33" subjects_affected="33" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="134" subjects_affected="93" subjects_at_risk="340"/>
                <counts group_id="E2" events="71" subjects_affected="53" subjects_at_risk="345"/>
                <counts group_id="E3" events="22" subjects_affected="14" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="77" subjects_affected="58" subjects_at_risk="340"/>
                <counts group_id="E2" events="38" subjects_affected="30" subjects_at_risk="345"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="340"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="345"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Science Director</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

